Evogene Ltd.

EVGN Healthcare Biotechnology

In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

0.39 0.01 −2.50%
Market cap
$6.3M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−20.48
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(100.03%) (115.46%) (63.29%) (18.64%)

+8 more TTM periods

Piotroski F-Score
2 3 4 3
ROA
(38.31%) (45.04%) (28.33%) (8.30%)
ROIC
0.00% 0.00% 0.00% (605.29%)
Return on Tangible Assets
(109.23%) (113.85%) (65.27%) (15.31%)
Average Days of Receivables
310.59 336.89 178.28 326.06
Free Cash Flow per Share
(0.88) (1.15) (1.72) (1.81)
Free Cash Flow
(10.78) (11.19) (13.56) (15.80)
Other line items

Show all line items

Columns are period end dates